Navigation Links
Beckman Coulter Prices $500 Million Senior Notes Offering

ORANGE COUNTY, Calif., May 18 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer and marketer of products that simplify, automate and innovate complex biomedical testing, announced today the pricing of its senior notes offering of:

  • $250 million of Senior Notes that mature in 2015 and bear interest at a rate of 6%, and

  • $250 million of Senior Notes that mature in 2019 and bear interest at a rate of 7%.


This offering is being made pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission and is expected to close May 21, 2009, subject to customary conditions. Citigroup Global Markets Inc., J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated are acting as active joint book-running managers for the offering.

Beckman Coulter expects to use the net proceeds from this offering of approximately $495 million to finance a portion of the acquisition price for the diagnostic systems portion of Olympus Corporation's Life Science business and for general corporate purposes. Pending the application of the net proceeds, Beckman Coulter plans to invest the net proceeds in U.S. government obligations, bank deposits or in other secure, short-term investments.

Certain statements in this news release may be deemed to include forward-looking statements, such as statements that relate to this offering and whether Beckman Coulter will consummate this offering. Forward-looking statements are typically identified by words or phrases, such as "believe," "expect," "anticipate," "intend," "estimate," "may increase," "may fluctuate," "plan," "goal," "target," "strategy," and similar expressions or future or conditional verbs such as "may," "will," "should," "would," and "could." These statements are based on current expectations, forecasts and assumptions and are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, including economic, market and monetary policy risks; operational risks; investment performance, fiduciary, and asset services risks; credit risks; liquidity risks; holding company risks; regulation risks; litigation risks; tax and accounting risks; strategic and competitive risks; and reputation risks. For a further list and description of risks and uncertainties associated with Beckman Coulter's business, see reports filed by Beckman Coulter with the Securities and Exchange Commission, including the "Risk Factors" section in the most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission. Beckman Coulter disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release is neither an offer to sell nor a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offering of these securities will be made only by means of a prospectus and related prospectus supplements. When available, copies of the prospectus and related prospective supplements may be obtained by calling Citigroup Global Markets Inc. toll-free at 1-877-858-5407, by mailing J.P. Morgan Securities Inc., Investment Grade Syndicate Desk, 270 Park Ave, New York, NY 10017, or by mailing Morgan Stanley & Co. Incorporated, Prospectus Department, 1585 Broadway, New York, NY 10036 or calling toll-free at 1-866-718-1649.

About Beckman Coulter

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care.

    Contact:   Cynthia Skoglund,                   (714) 773-7620
               Manager, Investor Relations

SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would ... named to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies ... FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by as ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor ... company focused on the discovery, development and commercialization of ... Ph.D., Chief Executive Officer, is scheduled to present at ... 2015 at 10:50 a.m. EST, at The Lotte New ... . . --> ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
Breaking Biology News(10 mins):